Pfizer, BioNTech begin phase 2/3 Covid-19 trial with BNT162b2 vaccine candidate

Pfizer and BioNTech have commenced phase 2/3 Covid-19 trial with BNT162b2 vaccine candidate. (Credit: Gerd Altmann from Pixabay)